Earnings History Data for VistaGen Therapeutics, Inc. (VTGN) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

VistaGen Therapeutics, Inc.

VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company's lead product candidate consists of AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder. VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
17-06-2025	AH		VTGN	VistaGen Therapeutics, Inc.	63.79	-0.43	-0.52	-0.25	VistaGen Therapeutics GAAP EPS of -$1.67 beats by $0.07, revenue of $0.48M misses by $0.23M [6/17/2025 4:32 PM]	2.09	-0.29 (-12.18%)	2.40	0.02 (0.84%)	1.90 - 4.21	400,073	150,000	1,883
VistaGen Therapeutics GAAP EPS of -$1.67 beats by $0.07, revenue of $0.48M misses by $0.23M [6/17/2025 4:32 PM] Vistagen targets transformative SAD drug approval with top-line PALISADE-3 data in Q4 2025 while advancing differentiated neuroscience pipeline [6/17/2025 6:50 PM] Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Report Preview: What to Look For [Jun-16-25 09:16AM] Stock Market Today: Dow, S&P 500 and Nasdaq marked lower as Trump says to 'evacuate Tehran' with Fed decision, retail sales on tap [2025-06-17 04:11AM] Results season slows to a dribble [2025-06-17 05:20AM] Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update [2025-06-17 04:30PM] Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Call Highlights: Strategic Advancements Amid ... [2025-06-18 03:01AM]
13-02-2025	AH		VTGN	VistaGen Therapeutics, Inc.	75.18	-0.46	-0.50	-0.22	VistaGen Therapeutics GAAP EPS of -$0.46 beats by $0.05, revenue of $0.23M beats by $0.05M [2/13/2025 4:33 PM]	2.95	0.10 (3.51%)	2.67	-0.18 (-6.47%)	2.22 - 5.74	255,795	230,000	2,079
VistaGen Therapeutics GAAP EPS of -$0.46 beats by $0.05, revenue of $0.23M beats by $0.05M [2/13/2025 4:33 PM] Vistagen advances Phase 3 SAD trials with 2025 data readout target [2/13/2025 8:55 PM] Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update [2025-02-13 04:30PM] Earnings To Watch: Vistagen Therapeutics Inc (VTGN) Reports Q3 2025 Result [Feb-12-25 07:51AM] Vistagen Therapeutics Inc (VTGN) Q3 2025 Earnings Call Highlights: Promising Trial Results and ... [2025-02-14 02:22AM] VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates [Feb-13-25 05:55PM]
07-11-2024	AH		VTGN	VistaGen Therapeutics, Inc.	85.22	-0.42	-0.40	-0.66	VistaGen Therapeutics GAAP EPS of -$0.42 misses by $0.03, revenue of $0.18M beats by $0.15M [11/7/2024 5:16 PM]	3.13	0.01 (0.32%)	3.13	0.01 (0.32%)	2.45 - 5.86	292,299	220,000	1,594
VistaGen Therapeutics GAAP EPS of -$0.42 misses by $0.03, revenue of $0.18M beats by $0.15M [11/7/2024 5:16 PM] Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Report Preview: What to Expect [Nov-06-24 07:51AM] Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update [2024-11-07 04:20PM]
13-08-2024	AH		VTGN	VistaGen Therapeutics	92.00	-0.35	-0.41	0.00	VistaGen Therapeutics GAAP EPS of -$0.35 beats by $0.06, revenue of $0.08M misses by $0.22M [8/13/2024 4:33 PM]	3.29	-0.10 (-2.95%)	3.39	0.0 (0.00%)	2.45 - 7.35	106,588	110,000	480
VistaGen Therapeutics GAAP EPS of -$0.35 beats by $0.06, revenue of $0.08M misses by $0.22M [8/13/2024 4:33 PM]
11-06-2024	AH		VTGN	VistaGen Therapeutics	104.00	-0.25	-0.34	0.00	VistaGen Therapeutics GAAP EPS of -$1.52 misses by $1.16, revenue of $1.06M beats by $0.86M [6/11/2024 4:23 PM]	3.69	-0.08 (-2.12%)	3.80	0.03 (0.80%)	1.62 - 24.71	97,042	130,000	880
Vistagen Therapeutics GAAP EPS of -$1.52 misses by $1.16, revenue of $1.06M beats by $0.86M [6/11/2024 4:23 PM]
13-02-2024	AH		VTGN	VistaGen Therapeutics, Inc.	132.41	-0.22	-0.31	-1.50	VistaGen Therapeutics GAAP EPS of -$0.22 beats by $0.08, revenue of $0.41M misses by $0.13M [2/13/2024 4:33 PM]	5.36	0.46 (9.39%)	5.09	0.19 (3.88%)	1.62 - 24.71	622,481	220,000	8,364
VistaGen Therapeutics GAAP EPS of -$0.22 beats by $0.08, revenue of $0.41M misses by $0.13M [2/13/2024 4:33 PM] Vistagen Therapeutics files for $350M mixed shelf [2/13/2024 5:04 PM]
09-11-2023	AH		VTGN	VistaGen Therapeutics, Inc.	32.53	-0.66	0.00	-2.40	VistaGen Therapeutics GAAP EPS of -$0.66 beats by $0.02, revenue of $0.28M [11/9/2023 5:07 PM]	2.56	-0.33 (-11.42%)	2.97	0.08 (2.77%)	1.62 - 24.71	1,146,608	390,000	10,116
VistaGen Therapeutics GAAP EPS of -$0.66 beats by $0.02, revenue of $0.28M [11/9/2023 5:07 PM]
28-06-2023	AH	4:30 PM ET (Jun 28)	VTGN	VistaGen Therapeutics, Inc.	370.66	N/A	0.00	-2.40	VistaGen Therapeutics GAAP EPS of -$8.51 misses by $0.11 [6/28/2023 4:32 PM]	1.78	0.06 (3.49%)	1.77	0.05 (2.91%)	1.62 - 32.10	159,371	390,000	8,753
VistaGen Therapeutics GAAP EPS of -$8.51 misses by $0.11 [6/28/2023 4:32 PM]
07-02-2023	AH	4:30 PM ET (Feb 7)	VTGN	VistaGen Therapeutics, Inc.	62.05	-0.05	-0.06	-0.05	VistaGen Therapeutics GAAP EPS of -$0.05 beats by $0.02, revenue of $0.18M misses by $0.13M [2/7/2023 5:03 PM]	0.1894	-0.07 (-27.38%)	0.22	-0.04 (-16.53%)	0.08 - 1.79	10,865,458	7,840,000	833,677
VistaGen Therapeutics GAAP EPS of -$0.05 beats by $0.02, revenue of $0.18M misses by $0.13M [2/7/2023 5:03 PM] VistaGen slips as mid-stage study for anxiety therapy remains on hold [2/8/2023 1:34 PM]
10-11-2022	AH	4:20 PM ET (Nov 10)	VTGN	VistaGen Therapeutics, Inc.	24.94	-0.08	-0.07	-0.07	VistaGen Therapeutics GAAP EPS of -$0.08 [11/10/2022 4:36 PM]	0.1554	0.03 (19.54%)	0.14	0.01 (4.69%)	0.08 - 2.39	7,950,024	2,700,000	58,958
VistaGen Therapeutics GAAP EPS of -$0.08 [11/10/2022 4:36 PM] Vistagen Reports Second Quarter Financial Results and Provides Corporate Update [Nov-10-22 04:30PM] VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates [Nov-10-22 06:45PM]
11-08-2022	AH	4:20 PM ET (Aug 11)	VTGN	VistaGen Therapeutics, Inc.	30.98	-0.10	-0.09	-0.04	VistaGen Therapeutics GAAP EPS of -$0.10 misses by $0.02, revenue of $0.31M beats by $0.07M [8/11/2022 4:30 PM]	0.1559	-0.02 (-10.91%)	0.16	-0.01 (-6.86%)	0.14 - 3.26	19,169,651	19,370,000	795,485
VistaGen Therapeutics GAAP EPS of -$0.10 misses by $0.02, revenue of $0.31M beats by $0.07M [8/11/2022 4:30 PM] VistaGen Therapeutics stock slips 13% after FQ1 revenue fall, bottom line miss [8/12/2022 1:39 PM] VistaGen Therapeutics Reports First Quarter Financial Results and Provides Corporate Update [Aug-11-22 04:20PM]
23-06-2022	AH	4:20 PM ET (Jun 23)	VTGN	VistaGen Therapeutics, Inc.	218.92	-0.08	-0.06	-0.20	VistaGen Therapeutics GAAP EPS of -$0.25 misses by $0.03, revenue of $1.11M misses by $0.21M [6/23/2022 4:22 PM]	0.9679	-0.07 (-6.93%)	1.02	-0.02 (-1.92%)	0.87 - 3.55	2,080,145	1,180,000	5,615
VistaGen Therapeutics GAAP EPS of -$0.25 misses by $0.03, revenue of $1.11M misses by $0.21M [6/23/2022 4:22 PM] VistaGen stock down 7% on disappointing FY result [6/24/2022 1:55 PM] VistaGen Announces Completion of PALISADE-1 Phase 3 Clinical Study of PH94B for the Acute Treatment of Social Anxiety Disorder [Jun-22-22 08:30AM] VistaGen Therapeutics Reports Fiscal Year 2022 Financial Results and Provides Corporate Update [Jun-23-22 04:20PM] VistaGen Therapeutics, Inc. (VTGN) Reports Q4 Loss, Misses Revenue Estimates [Jun-23-22 05:35PM]
10-02-2022	AH	4:20 PM ET (Feb 10)	VTGN	VistaGen Therapeutics, Inc.	311.54	-0.05	-0.08	-0.07	VistaGen Therapeutics GAAP EPS of -$0.05 beats by $0.02, revenue of $0.36M beats by $0.11M [2/10/2022 4:32 PM]	1.51	-0.03 (-1.95%)	1.64	0.10 (6.49%)	1.40 - 3.55	1,437,833	1,350,000	4,617
VistaGen Therapeutics GAAP EPS of -$0.05 beats by $0.02, revenue of $0.36M beats by $0.11M [2/10/2022 4:32 PM] VistaGen Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update [Feb-10-22 04:20PM] VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Tops Revenue Estimates [Feb-10-22 05:55PM]
10-11-2021	AH	4:25 PM ET (Nov 10)	VTGN	VistaGen Therapeutics, Inc.	476.47	-0.07	-0.05	-0.05	VistaGen Therapeutics EPS misses by $0.01, beats on revenue [11/10/2021 4:28 PM]	2.35	0.10 (4.44%)	2.27	0.02 (0.89%)	0.65 - 3.55	3,053,487	1,170,000	421
VistaGen Therapeutics EPS misses by $0.01, beats on revenue [11/10/2021 4:28 PM] VistaGen Therapeutics Reports Fiscal Year 2022 Second Quarter Financial Results and Provides Corporate Update [Nov-10-21 04:20PM] VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Tops Revenue Estimates [Nov-10-21 07:05PM] VISTAGEN THERAPEUTIC (VSTA) Q2 2022 Earnings Call Transcript [Nov-11-21 04:31AM]
12-08-2021	AH	4:15 PM ET (Aug 12)	VTGN	VistaGen Therapeutics, Inc.	530.19	-0.04	-0.05	-0.07	VistaGen Therapeutics EPS beats by $0.01, misses on revenue [8/12/2021 4:36 PM]	2.78	0.03 (1.09%)	2.75	0.0 (0.00%)	0.56 - 3.55	918,048	830,000	690
VistaGen Therapeutics EPS beats by $0.01, misses on revenue [8/12/2021 4:36 PM] VistaGen Therapeutics Reports Fiscal Year 2022 First Quarter Financial Results and Provides Corporate Update [Aug-12-21 04:25PM] VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue Estimates [Aug-12-21 08:05PM] VISTAGEN THERAPEUTIC (VSTA) Q1 2022 Earnings Call Transcript [Aug-13-21 06:31AM]
29-06-2021	AH		VTGN	Vistagen Therapeutics, Inc.	377.00	-0.20	-0.05	0.00	VistaGen Therapeutics EPS misses by $0.27, beats on revenue [6/29/2021 4:17 PM]	3.17	0.49 (18.28%)	2.69	0.01 (0.37%)	0.46 - 3.18	6,844,214	4,650,000	20,686
VistaGen Therapeutics EPS misses by $0.27, beats on revenue [6/29/2021 4:17 PM] VistaGen Therapeutics Reports Fiscal Year 2021 Financial Results and Provides Corporate Update [Jun-29-21 04:15PM] Why VistaGen Therapeutics Stock Jumped Today [Jun-30-21 04:14PM]
11-02-2021	AH		VTGN	VistaGen Therapeutics, Inc.	261.85	-0.07	-0.05	-0.15	VistaGen Therapeutics EPS misses by $0.02, beats on revenue [2/11/2021 4:54 PM]	1.90	-0.08 (-4.04%)	1.98	0.0 (0.00%)	0.30 - 2.94	2,448,488	2,554,831	42,576
VistaGen Therapeutics EPS misses by $0.02, beats on revenue [2/11/2021 4:54 PM]
12-11-2020	AH		VTGN	VistaGen Therapeutics, Inc.	48.17	-0.05	0.02	-0.13	VistaGen Therapeutics EPS of -$0.05 [11/12/2020 5:41 PM]	0.70	0.0 (-0.37%)	0.70	0.0 (-0.37%)	0.29 - 1.15	217,681	507,776	13,115